Panaji Journal

Food Allergy Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

 Breaking News
  • No posts were found

Food Allergy Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

January 26
21:01 2023
Food Allergy Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Food Allergy Pipeline Insight, 2023” report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in the Food Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Food Allergy Pipeline Report

  • DelveInsight’s Food Allergy pipeline analysis depicts a robust space with 30+ active players working to develop 35+ Food Allergy pipeline treatment therapies.
  • The leading Food Allergy companies proactively working to develop potential drug candidates to improve the Food Allergy treatment options include Merck & Co, AstraZeneca, Mabylon, GI Innovation, Aimmune Therapeutics, Inc, Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc, Vedanta Biosciences, Inc, Regeneron Pharmaceuticals, Genentech, Inc, Camallergy, Aravax, Inimmune, Prota therapeutics, Intrommune Therapeutics, Alladapt Immunotherapeutics, Siolta Therapeutics, IgGenix,  Rho Federal Systems Division, Inc, and many others.
  • Promising Food Allergy pipeline therapies such as Viaskin Peanut/DBV712, CA002, Omalizumab, Ligelizumab, Dupixent, Viaskin Milk, ADP101, PVX108, INT 301, PRT100, STMC-103H, AR601, and others are under development in different phases of clinical trials.
  • The Food Allergy Companies and academics that are working to assess challenges and seek opportunities that could influence Food Allergies R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

 

To explore more information on the latest breakthroughs in the Food Allergy Pipeline treatment landscape of the report, click here @ Food Allergy Pipeline Outlook

 

Food Allergy Overview

A food allergy occurs when the body’s immune system sees a certain food as harmful and reacts by causing symptoms. This is an allergic reaction. Foods that cause allergic reactions are allergens. The results of skin prick tests (SPT), IgE total and specific antibodies, and patient histories are not predictive of true food allergy, as they are not able to establish the causal and temporal relationship between the intake of the suspect food and the hypersensitivity reaction. The negative predictive accuracy of a skin prick test weal of < 3mm greater than the negative control is high, usually > 95%, and is strong evidence that the food may be consumed without severe, immediate food-allergic reactions. A positive SPT, even a weal of 3 mm or more, may be clinically irrelevant, as the patient may tolerate the ingested food.

 

Recent Developments Activities in the Food Allergy Treatment Landscape

  • In April 2022, Intrommune Therapeutics, announced that its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy had been amended to allow determination of the Maximum Tolerated Dose (MTD). As previously disclosed, Cohort 1 completed up-titrating to Dose 4 with no significant adverse events. Patients with peanut allergy in Cohort 2 were started at Dose 2 and are being up-titrated through 11 increasing doses of INT301 to determine both an MTD and a safe starting dose. Patients in Cohort 3 are starting at Dose 3 and participants in Cohort 4 are expected to start at Dose 4. Cohort 2 has successfully up-titrated participants through 11 doses. Cohort 3 is currently enrolling. To date, there have been no significant adverse events.
  • In March 2022, Aravax, announced that it had received a green light for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA). PVX108 is a next-generation, allergen-specific immunotherapy using peptides that represent critical fragments of peanut proteins to precisely target the T cells driving peanut allergy.
  • In January 2022, Alladapt Immunotherapeutics Inc., announced the completion of patient enrollment in Harmony, its Phase 1/2 study of ADP101 for the treatment of food allergy (FA).DP101, the Company’s lead program, is a potentially best-in-class oral immunotherapy (OIT) designed to desensitize patients allergic to one or multiple foods simultaneously to mitigate the risk of severe, life-threatening allergic reactions.
  • In March 2021, Cambridge Allergy Ltd announced it has been awarded £1.1M funding under the Innovate UK Biomedical Catalyst Award program administered by Innovate UK, the United Kingdom’s research and innovation agency. The company planned to use the £1.1M in non-dilutive funding to accelerate the Company’s peanut allergy immunotherapy, CA002.
  • Omalizumab is an investigational product, which is being developed by Genetech. Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody designed to selectively bind to human immunoglobulin E (IgE). This molecule is being developed in collaboration with Novartis. This drug is in the Phase III stage of development for the treatment of food allergy.

 

Request a sample and discover the recent advances in Food Allergy Ongoing Clinical Trial Analysis and Medications, click here @ Food Allergy Treatment Landscape

 

Food Allergies Emerging Drugs Profile

 

Viaskin Peanut: DBV technologies

Investigational Viaskin® Peanut therapeutic treatment is based on epicutaneous immunotherapy, or EPIT™.   This potential new class of immunotherapey is designed to work by delivering allergens to the immune system through intact skin using our proprietary Viaskin® technology. For those patients facing potentially life-threatening food allergies, this potential immunotherapy treatment aims to desensitize them to allergens by delivering compounds in small quantities into the outer layers of the skin. The investigational EPIT aims to target specific epidermal dendritic cells, called Langerhans cells. Pre-clinical research has shown that these cells capture antigens and migrate to the lymph node in order to activate the immune system.

 

Omalizumab: Genentech

Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE), which treats asthma and chronic idiopathic urticaria symptoms by limiting the allergic response Label. It inhibits IgE binding to receptors on mast cells and basophils, blocking the IgE-mediated secretion of inflammatory mediators from these cells. Omalizumab, manufactured by Genentech, was first FDA approved in 2003 to treat adults and children 12 years of age and older with moderate to severe persistent allergic asthma which is not controlled by inhaled steroids. Since its U.S. approval, more than 200,000 patients older than 12 with allergic asthma have been treated. In September 2018, a new prefilled syringe formulation of this drug was approved by the FDA. Genentech and Novartis Pharmaceuticals Corporation are working closely with NIAID and the Consortium of Food Allergy Research to start a potentially pivotal study assessing the efficacy and safety of Xolair in multiple food allergies. It is currently being evaluated in the Phase III stage of development for treating Peanut Allergy patients.

 

Dupilumab: Regeneron Pharmaceuticals

Dupilumab is a human monoclonal antibody that is an interleukin-4 (IL-4) receptor alpha antagonist. Dupilumab is designed by Regeneron using VelocImmune® technology. It is an immunoglobulin G4 subclass human monoclonal antibody that work by blocking the IL-4 and interleukin-13 (IL-13) signalling by binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes. It is a potential monotherapy administered subcutaneously to the pedantic patients with peanut allergy.

 

ADP101: Alladapt Immunotherapeutics

ADP101 is a proprietary, standardized, oral immunotherapy drug candidate that is being studied for the treatment of food allergy to one or more foods. ADP101 is formulated to consistently deliver a well-characterized investigational drug product sourced from the most commonly allergenic food groups and designed to be administered as part of a clinically monitored dosing protocol. The goal of oral immunotherapy is to induce a state of clinically meaningful desensitization to food proteins, defined as the absence of moderate or severe allergic reaction following the ingestion of small but potentially dangerous amounts of food. ADP101 is based on an intellectual property estate that includes patents and accompanying clinical data licensed from Stanford University.

 

Food Allergy Pipeline Therapeutics Assessment

There are approx. 30+ key companies which are developing the therapies for Food Allergies. The companies which have their Food Allergies drug candidates in the most advanced stage, i.e. preregistration include, DBV technologies.

 

For further information, refer to the detailed Food Allergy Unmet Needs, Food Allergy Market Drivers, and Market Barriers, click here for Food Allergy Ongoing Clinical Trial Analysis

 

Scope of the Food Allergy Pipeline Report

 

  • Coverage- Global

 

  • Food Allergy Companies- Merck & Co, AstraZeneca, Mabylon, GI Innovation, Aimmune Therapeutics, Inc, Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc, Vedanta Biosciences, Inc, Regeneron Pharmaceuticals, Genentech, Inc, Camallergy, Aravax, Inimmune, Prota therapeutics, Intrommune Therapeutics, Alladapt Immunotherapeutics, Siolta Therapeutics, IgGenix,  Rho Federal Systems Division, Inc, and others.

 

  • Food Allergy Pipeline Therapies- Viaskin Peanut/DBV712, CA002, Omalizumab, Ligelizumab, Dupixent, Viaskin Milk, ADP101, PVX108, INT 301, PRT100, STMC-103H, AR601, and others.

 

  • Food Allergy Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Food Allergy Market Drivers and Food Allergy Market Barriers, click here @ Food Allergy Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Food Allergies: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Food Allergies – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. Viaskin Peanut: DBV technologies
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Dupilumab: Regeneron
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. ADP101: Alladapt Immunotherapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Research programme : antiallergy therapeutics: IgGenix
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Food Allergies Key Companies
  21. Food Allergies Key Products
  22. Food Allergies- Unmet Needs
  23. Food Allergies- Market Drivers and Barriers
  24. Food Allergies- Future Perspectives and Conclusion
  25. Food Allergies Analyst Views
  26. Food Allergies Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Food Allergy Mergers and acquisitions, Food Allergy licensing activities @ Food Allergy Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services